FDA approves first-in-class treatment for myasthenia gravis
(HealthDay)—Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Food ...
Dec 21, 2021
0
6